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Successful adoptive immunotherapy (AIT) for cancer relies on the infusion of in
vitro expanded, tumor-reactive lymphocytes with a goal of generating productive tumor
immunity. Previously, our lab has developed a protocol to activate selectively tumorreactive T lymphocytes in vitro using two pharmacologic agents, bryostatin-1 and
ionomycin. Following the pharmacological stimulation, conventionally, IL-2 is added to
stimulate in vitro proliferation. In this report, alternate cytokines from the common
cytokine receptor γ-chain family, namely IL-7 and IL-15, were explored as the alternative
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cytokine supplements. We found that tumor DLN cells activated in vitro with B/I and
cultured in IL-7/15 alternate common γ-chain cytokines expanded better than IL-2 cultured
cells. Furthermore, immunosuppressive myeloid-derived suppressor cells from the tumor
microenvironment were targeted with a chemotherapeutic agent, gemcitabine. Despite
combining gemcitabine and the T lymphocytes expanded in IL-7/15, AIT failed to induce
regression of large established 4T1 mammary flank tumors.
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CHAPTER 1 Introduction

1.1 Cancer: Challenges
Despite the advances in cancer research, according to a 2009 American Cancer
Society report, cancer accounts for nearly one-quarter of deaths next to only heart diseases
in the United States alone. Worldwide, one in eight deaths is due to cancer and it exceeds
the number of deaths caused by AIDS, tuberculosis, and malaria combined. The
corresponding estimates for total cancer deaths in 2007 were 7.6 million, or about 20,000
cancer deaths a day, with 2.9 million in economically developed countries and 4.7million
in economically developing countries. By 2050, the global burden is expected to grow to
27 million new cancer cases and 17.5 million cancer deaths. Moreover, both the direct and
indirect financial cost of cancer is also extensive (1).
Cancer cells are defined by the lack of regulation in cell proliferation and
homeostasis. Several research findings indicate that tumorigenesis in humans is a multistep
process and these genetic altering steps drive the transformation of normal human cells
into highly malignant derivatives. Hanahan et al. categorizes the six main physical
alterations common in cancer cells as: self-sufficiency in growth signals, insensitivity to
growth-inhibitory signals, evasion of programmed cell death (apoptosis), limitless
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replicative potential, sustained angiogenesis, and tissue invasion and metastasis (2). Cancer
cells escape the terminal differentiation and quiescence steps important in normal cell
homeostasis. In order to obtain such properties, tumor cells produce their own growth
factors or transform the normal growth factors from the hosts. Furthermore, the signaling
pathways of mitogenic stimuli are constitutively activated by overexpression or by
mutation of signal transduction signals in tumor cells. Tumor cells can also directly deregulate cell cycle regulation. Cancer cells obtain these new characteristics to avoid the
antitumor defense mechanisms of the normal cells. Deregulations in these multiple
regulatory circuits act as rate-limiting steps in tumor progression and add to the complexity
of cancer cells (3).
There are several methods to treat cancer including surgery, radiation,
chemotherapy, hormones, and immunotherapy. While standard treatments, like
chemotherapy and radiation therapy, are used on cancer patients, the toxicity of adverse
reactions can be a serious problem (4). On the other hand, immunotherapy is a relatively
nontoxic cancer therapy that can be used alone or in conjunction with other therapies (5).
The goal of immunotherapy is to use the host immune system to augment protective
antitumor immunity and to disrupt the regulatory circuits that maintain tumor progression
and tolerance (6).

1.2 Overview of Innate and Adaptive Antitumor Immunity

2

The idea that the immune system can recognize and respond to carcinomas, which
are after all derived from the host, was first proposed by Paul Ehrlich in 1909. However, it
was not until the 1950s, as immunologists gained a better understanding of transplantation
and tumor immunobiology, that the Ehrlich theory could be validated. With the availability
of inbred strains of mice, the animal models demonstrated that the syngeneic transplants of
tumors were immunologically distinguishable from normal cells. Macfarlane Burnet and
Lewis Thomas formally introduced the term “immunosurveillance” to describe the
endogenous immune system components recognizing and eliminating the nascent
transformed cells (7, 8).
In addition to identifying the cellular effectors of cancer immunosurveillance, two
additional key studies revealed the effector functions of these cellular immune
components. First, Dighe et al. showed that endogenously produced interferon γ (IFN- γ)
protected the host against the growth of transplanted tumor and the formation of primary
chemically induced and spontaneous tumors (10). The second important observation was
that C57Bl/6 mice lacking perforin were more vulnerable to MCA-induced tumor
formation compared to the naïve wild-type mice. Perforin is a part of the cytolytic granules
of cytotoxic T cells and natural killer (NK) cells that is involved in lymphocyte-dependent
killing of many different target cells, including tumor cells (7, 8).
The host immune system can be categorized into two general responses: innate and
adaptive immune response (see appendix A). The innate immune response refers to the
first line of barriers to combat a wide range of pathogens but lacks pathogen specificity and
3

longevity. In addition to the physical and chemical barriers of the host, the innate immune
system has cellular component including granulocytes and natural killer cells. In contrast,
an adaptive immune response takes time to develop and is highly specific to the pathogen.
The adaptive immunity involves the selection and amplification of clones of lymphocytes
(B and T cells) bearing receptors that recognize the foreign antigen (a term derived from a
substance that can stimulate antibody generation) (11, 12). The adaptive immune system
can be further divided into humoral and cellular adaptive immunity. The former refers to
the B cell receptors recognizing antigens from the extracellular environment and
differentiating into effector plasma cells that secrete antibodies and into memory B cells.
However, it is the function of the T lymphocytes, also known as the cell-mediated immune
response, which control intracellular pathogens, to activate B cell responses to most
pathogens, and play a key role in maintaining antitumor immunity.
T lymphocytes develop in the thymus and are composed of two main classes: one
of which has a surface marker CD4 (CD4 T cells) and the other with CD8 (CD8 or
cytotoxic T cells). The CD4 T cells are activated by the antigen epitopes bound to MHC II
which are only located on the antigen-presenting cells (B cells, macrophages and dendritic
cells). The CD4 effector subsets currently characterized are: T helper (TH) cells (which can
be divided into TH1 and TH2 cells), TH17, and several regulatory T cell subsets. TH1 cells
have a dual function of controlling intracellular pathogens and activating macrophages via
various cytokines such as interleukin-2 (IL2), tumor necrosis factor-β (TNF-β), and
interferon-γ (IFN- γ). TH2 cells are entirely dedicated to the activation of the naïve B cells
to produce antibody. TH17 cells help to recruit neutrophils to sites of infection early in the
4

adaptive immune response. Regulatory T cells (Tregs) tend to inhibit immune activities
and are important in preventing uncontrolled immune responses and autoimmunity (11,
12).
There are several key findings that demonstrate the cellular basis of cancer
immunosurveillance and involvement of both the adoptive and innate immune responses.
One of the studies involved the gene-target mice lacking the recombinase activating gene
(RAG-2). Mice lacking either RAG-2 or its obligate partner, RAG-1, cannot rearrange
lymphocyte antigen receptors, which inhibits production of peripheral αβ T cells, B cells,
natural killer cells, or γδ T cells. The importance of RAG-2 study is that RAG-2 expression
is limited to cells of the lymphoid system, thus allowing researchers to exclusively study
the effects of host lymphocyte deficiency. After subcutaneous injection of the chemical
carcinogen 3’-methycholanthrene (MCA), RAG-2 knockout mice (RAG-2-/-) developed
sarcomas at the injection site faster and with greater frequency when compared with the
control group. RAG-2-/- mice were also more prone to spontaneous epithelial tumors.
These findings reveal that lymphocytes are important protectors against both chemicallyinduced and spontaneous tumor formation. Furthermore, Smyth et al. demonstrated that
natural killer (components of innate immune system) and natural killer T cells also
participate in cancer immunosurveillance. C57BL/6 mice, depleted of both natural killer
and natural killer T cells using the anti-NK1.1 mAb, were two or three times more
susceptible to MCA-induced tumorigenesis (7, 8, 9).
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Cytotoxic T cells carry CD8 surface marker and are stimulated by the antigenic
peptide bound to major histocompatibility complex class I (MHC I) which are found on all
nucleated cells (12). CD8 T cells have been identified as potent effectors of the adaptive
antitumor immune response. The antigenic peptides recognized by these CD8 T cells are
mostly non-mutated self-antigens that are also expressed by tumor cells. Although tumorspecific CD4 T cells have also been identified, CD4 T cells can either help or hinder
antitumor immune responses due to maintenance of Tregs (13). Since the first human
tumor antigen was identified in 1991, many tumor antigens have been cloned. Different
types of tumor antigens can be broadly classified into five categories: 1) cancer testis
antigen, 2) tissue differentiation antigens, 3) overexpressed antigens, 4) unique tumor
antigens and 5) viral antigens. In addition to tumor antigens presented on MHC molecules,
transformed tumor cells also overexpress other molecules that can be recognized by the
adaptive immune system as neoplastic (8). For example, among the most studied
overexpressed oncogenic proteins is HER-2/neu. HER-2/neu is a growth factor receptor
that is overexpressed in 30% of breast and ovarian cancers and other adenocarcionmas.
Numerous studies have shown that antibody, helper T cell and cytotoxic CD8 T cell
respond against HER-2/neu-positive cancer cells (14). Thus due to the immunogenicity of
tumor cells, T lymphocytes can be used in immunotherapy to fight cancer.

1.3 Adoptive Immunotherapy: Opportunities

6

Immunotherapy can be categorized into two types: active and passive. The active
immunotherapy stimulates the patient’s own immune system by direct administration of
therapeutic cancer vaccines in vivo (12). Cancer vaccines include genetically modified
tumor cells, antigen-loaded dendritic cells, and purified tumor antigens all aim to stimulate
the adoptive immune system (17). However, in spite of large number of patients treated
with vaccines, exceedingly low objective response rates are reported and cancer vaccines
used alone cannot induce regression of invasive, vascularized tumors. Moreover, although
immune T cells sensitive to tumor antigens can be generated by direct immunization
(active immunotherapy), there are no cancer vaccine models that demonstrate that
vacularized tumors can be rejected by this method. On the other hand, the passive
immunotherapy has been more encouraging and shown consistent antitumor effects in
rejecting large vascularized tumors in mice under appropriate conditions (16). Passive or
adoptive immunotherapy (AIT) refers to the reintroduction of the cancer-reactive T cells,
originally harvested from the cancer patients, which are then expanded and manipulated in
vitro in order to generate productive antitumor responses (12, 6).
In adoptive immunotherapy, various mature T lymphocytes with antitumor activity
are transferred into a tumor-bearing host with the goal of eliminating a tumor and
preventing its recurrence (15). Three criteria are required for such immunologic destruction
of established tumors: 1) sufficient numbers of immune cells must be generated in vivo
that are highly sensitive to tumor antigens, 2) these immune components must traffic to
and infiltrate the tumor stroma, and 3) once reaching the tumor site, these immune
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effectors must manifest appropriate actions such as direct lysis or cytokine secretion than
can cause tumor destruction (16).
When planning for successful AIT, the following factors must be taken into
consideration: tumor type, route of AIT of immune effector cells, stage or size of tumor to
be treated, location of tumor, immune effector cells to be transferred, source of effector
cells, and the mechanism for ex vivo stimulation of effector cells including additional
drugs or cytokines. When selecting a tumor model, since human tumors are weakly
immunogenic, using too immunogenic tumor strain can result in deceptively easy tumor
rejection. Also, generation of highly active T lymphocytes with specific reactivity against
tumor antigen is critical for effective AIT (18). Although lymphokine-activated killer cells
(LAK) and monocytes/macrophages can be used as AIT effectors cells, T cells have been
identified as the most potent effectors of the adaptive antitumor immune response (12).
Specifically, CD8 cytotoxic T lymphocytes are the primary effector cells used in adoptive
T cell therapy.
There are various potential sources of T cells from the tumor-bearing host,
including peripheral blood, tumor biopsies, lymph nodes and spleen. Obtaining T cells
from the peripheral blood may be easier but higher frequency of tumor reactive T cells can
be found in tumor biopsies (tumor-infiltrating lymphocytes) (6). However, harvesting
sufficient amount of tumor-infiltrating lymphocytes can be difficult, though, this approach
has been used successfully in patients with melanoma (18). Furthermore, tumor-infiltrating
lymphocytes may require co-administration of high-dose interleukin-2 in generating
antitumor responses in vivo, which may be harmful to the patients. The spleen can also be
8

a source of lymphocytes though the immunizing tumor cells need to be strongly
immunogenic in order to activate the spleen cells. Based on our lab’s previous findings, the
lymph nodes draining the primary tumor site have been a good source of tumor reactive T
lymphocytes. We have found that the popliteal lymph nodes contain T lymphocytes once
they are activated by the tumor cells injected into a footpad. Adoptive transfer of these
effector cells after further activation and expansion in vitro into the tumor-bearing host can
be delivered by intravenous (IV) (12).
For adoptively transferred T cells to proliferate and maintain effector functions in
vivo, the host environment must be also prepared to optimize the AIT. One of the ways to
precondition a favorable host environment is by lymphodepletion. According to Gattitoni
et al., lymphopenic environment enables tumor-reactive T cells to destroy large tumors
more effectively (13). Their finding is based on the long observation in mouse models that
showed depletion of immune cells before AIT markedly improved the antitumor efficacy
of transferred CD8 T cells. Although removing the host immune system for the efficacy of
AIT seems counter-intuitive, there are several mechanisms that may explain the augmented
efficacy. These factors include the elimination of host immunosuppressive cells such as
CD4+ CD25+ regulatory T cells (Tregs), the depletion of endogenous cells competing for
activating cytokines, and availability of antigen-presenting cells (APCs) (13).
Host immunosuppression in tumor-bearing hosts can be caused by several factors.
Tregs are important for the maintenance of peripheral self-tolerance but suppress antitumor
responses. Tregs represent about 5 to 10% of the CD4 T cell population and constitutively
express CD25 (also known as IL2-Rα). They are also characterized by expression of the
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transcription factor forkhead box P3 (Foxp3). Although Tregs control the key aspect of
tolerance to self-antigens, tumor-associated antigens also derived from the self-antigen are
masked by the Tregs and avoid the host immune system leading to detrimental
immunosuppression (19). Other immune cells, including natural killer (NK) cells, natural
killer T (NKT) cells, and most importantly myeloid-derived suppressor cells (MDSCs)
have been demonstrated to suppress T cell functions. Although less is revealed about the
immunosuppressive effects of NK and NKT cells, more is known about MDSCs. This
heterogeneous cell population is composed of myeloid-derived lineage cells at various
stages of differentiation, including monocytes, granulocytes, and dendritic cells. Increased
frequencies of MDSCs have been reported with tumor progression and T cell dysfunction
(13).
Furthermore, adoptively transferred antigen-specific T cells represent a small
portion of the total T cell population residing in the host. Competition exists between
transferred and irrelevant host T cells for a limited amount of resources such as cytokines
and antigens required to support transferred CD8 T cell homeostasis for AIT. Such
competition is known as the “cytokine sink” effect. Lymphodepletion can overcome
cytokine sink effects and also decreases the competition at the surface of antigen-bearing
antigen-presenting cells (APCs). Although lymphodepletion can reduce the number of
APCs in vivo, it has been also linked to increasing the number of mature activated APCs
which can facilitate the activation of transferred tumor-reactive T cells in vivo (13).
Host preconditioning by lymphodepletion can be achieved by several mechanisms
including total body irradiation, genetic alteration, and systematic chemotherapy. Our lab
10

has administered the cytotoxic chemotherapy agent, cyclophosphamide (CYP), to
precondition the host environment for AIT. Cyclophosphamide is a synthetic antineoplastic
drug and an alkylating agent that interferes with the growth of rapidly proliferating cells.
One possible mechanism of action is by cross-linking of tumor cell DNA (20).
Cyclophosphamide has also been shown to remove tumor-induced suppressor T cells.
Lutisak et al. demonstrated the mechanisms by which CYP can both decrease the number
of Tregs and inhibit the suppressive capability of Tregs. Their results showed that lowdose CYP administration decreases expressions of GITR and Foxp3 which are important in
Treg function while enhancing apoptotic events and suppressing homeostatic proliferation
of Tregs (19).

1.4 Cytokines: Supplement to AIT
Successful adoptive immunotherapy requires not only a transfer of tumor-reactive
T cells into the tumor bearing host, but also in vitro expansion of cancer-reactive T cells
(6). Administration of cytokines has been known to amplify the AIT effect (12).
Especially, the cytokines that use the receptors of the common cytokine-receptor γ-chain
family (γc cytokines) are important for regulating T cell responses and stimulating T cell
growth (21). Among the γc cytokines, interleukin-2 (IL-2), IL-7, and IL-15 are the critical
cytokines for regulating lymphoid homeostasis. These cytokines can stimulate T cell
activation, survival and proliferation in vitro. The common γc component in the receptors
for these cytokines stimulates intracellular MAP kinase and PI3 kinase pathways that result
in mitogenic and antiapoptotic signals (22).
11

Activated CD4 and CD8 T cells produce IL-2 in response to T cell receptor ligation
which binds to the heterotrimeric receptors that include IL-2Rα, IL-2/15Rβ, and γc (12,
22). IL-2Rα recognizes IL-2 specifically with low affinity and has a short cytoplasmic
domain. IL-2/15Rβ, as the name indicates, is a receptor chain that is shared both by the IL2 and IL-15 receptor. Once activated, it stimulates JAK3-, STAT5-, and AKT-dependent
signaling pathways which are involved in cellular survival and proliferation. Studies with
gene-targeted knockout phenotypes revealed IL-2 is critical in supporting T cell activation,
and to a lesser degree, macrophages, natural killer cells, and B cells (12).
IL-15 is a both T cell and natural killer cell stimulatory factor (23). IL-15 and IL15Rα are expressed in thymus and support the intrathymic differentiation of T cells. The
IL-15 receptor resembles the IL-2 receptor in that it is also a heterotrimeric receptor with
IL-15Rα chain instead of the IL-2Rα chain and it binds to IL-15 with a high affinity (22).
Although both IL-2 and IL-15 are similar in structure and function, they do have some
contrasting functions. IL-2 can promote activation-induced T cell death while IL-15
inhibits cellular death (23). Moreover, IL-15 enhances the proliferative capacity of
memory T cell subsets (24). Memory T lymphocytes are a dynamic repository of antigensensitized T lymphocytes that accumulate overtime. They provide immediate protection in
peripheral tissues and increase recall responses to antigens in secondary lymphoid organs
(25). Schluns et al. demonstrated that IL-15 and IL-15Rα are required to generate memory
phenotype CD8 T cells in unimmunized mice and tumor-antigen specific memory CD8 T
cells (21).
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While IL-15 signals are important in supporting memory CD8 T cell proliferation,
the survival of the memory T cell population is supported by another common γc chain
cytokine, IL-7. IL-7 contributes to the survival and proliferation of thymocytes during
early stages of T cell development (23). The IL-7 receptor is a heterodimer with an IL-7α
component which binds specifically to IL-7. Animals with deficient IL-7 or IL-7Rα
demonstrated severe defects in T cell differentiation and deficiencies of both B and T
lymphocytes indicating the importance of IL-7 in T cell development. IL-7 may also
promote thymocyte survival by upregulating antiapoptotic thymocyte Bcl-2 expression
(22). Furthermore, in vitro administration of IL-7 has been shown to enhance proliferation
and survival of mature T cells, while exogenous IL-7 in vivo administration increased the
numbers of CD4 and CD8 T cells (23).
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CHAPTER 2 Phenotyping different stages of T cell differentiation

stimulated by both pharmacological agents and alternate
gamma-chain cytokine family

2.1 Introduction
Successful adoptive immunotherapy for cancer relies on the infusion of in vitro
expanded, tumor-reactive lymphocytes with the goal of generating protective tumor
immunity (6). Among the lymphocytes, CD8 cytotoxic T cells have been demonstrated as
potent mediators of antitumor immunity (13). In order to activate and grow tumor-specific
cytotoxic T lymphocytes, these lymphocytes must be periodically stimulated with
autologous tumor antigen. Tumor cells can be used as stimulators but they may secrete
immunosuppressive factors and are not clinically practical, since large amount of tumor
cells are required. Thus, our lab has developed a protocol to activate selectively the tumorreactive T lymphocytes in vitro using two pharmacologic agents, bryostatin-1 and
ionomycin. When T cells from the tumor-sensitized murine draining lymph nodes were
activated with bryostatin-1 and ionomycin along with low-dose IL-2, not only did the
lymphocytes expand better in vitro but also demonstrated antitumor efficacy in vivo (26,
27).
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Exposure to both bryostatin-1 and ionomycin mimics an important T cell activation
pathway (28). Following the ligation of tumor antigen with the T cell receptor, various
proximal signaling complexes lead to activation of phospholipase C (PLC) which includes
Ca2+ and DAG-induced responses. Phospholipase C is phosphorylated and activated by
SLP-76, Vav 1, and LAT after T cell receptor ligation. Activated PLC then hydrolyzes the
membrane lipid PI (4,5)P2 producing the second messengers inositol triphosphate (IP3) and
diacylglycerol (DAG). The second messenger IP3 stimulates Ca2+ permeable ion channel
receptors (IP3R) on the endoplasmic reticulum (ER) membrane, leading to the release of
ER Ca2+ stores into the cytoplasm. T cell receptor induced production of DAG results in
the activation of two pathways involving Ras and protein kinase C (PKC). PKC then
phosphorylates numerous protein substrates downstream which activate genes involved in
the function, survival, activation and homeostasis of T cells (29).
Brostatin-1 belongs to a class of macrocyclic lactones and is derived from marine
bryozoans, Bugula neritina. It binds to the regulatory domains of protein kinase C (PKC)
and regulates the pathway by both activation and inhibition. Short-term treatment of
bryostatin-1 activates PKC while a long-term exposure results in PKC inhibition (30). It
also has many immunomodulating properties including stimulation of IL-2 production and
interferon-gamma in human peripheral blood lymphocytes, induction of IL-2 receptor on
human T lymphocytes and inhibition of natural killer and lymphokine-activated killer
(LAK) cells (31). However, it does not have tumor promoting properties that some other
PKC activators (phorbol esters) demonstrate. Ionomycin is a calcium ionophore which
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increases the intracellular Ca2+ concentration which are universal second messengers in
eukaryotic cells (29, 33).
In addition to the pharmacologic agents, cytokines are also known to regulate T
lymphocyte differentiation, survival and proliferation (23). Cytokines also play an
important role in the differentiation of memory T cells. Memory is the hallmark of the
adaptive immune system and is the ultimate goal of a protective immune response. There
are four main events linked to the generation of memory T cells. These events include:
initiation, clonal expansion, contraction and memory generation (21). Once the naïve T
cells complete their maturation in the thymus, mature T cells circulate through the
bloodstream and peripheral (secondary) lymphoid organs. Before activation, these naïve T
cells maintain a low metabolic rate and divide only occasionally (homeostatic
proliferation). T cells are activated when their receptors recognize a foreign antigen bound
to MHC molecules and by interacting with the costimulatory receptor, which initiates a
cascade of transcriptional and translational signals that allows for clonal expansion and
acquisition of effector functions. After a vigorous clonal expansion phase, the great
majority of effectors cells are eliminated by apoptosis during the contraction phase. A
subpopulation of T cells remaining persists as memory T cells (33).
While IL-2 is critical in promoting effector T cell survival, T cell activation, and to
a lesser degree, macrophages, natural killer cells, and B cells, IL-2 also enhances
activation-induced cell death (AICD) of lymphocytes as a mechanism of self-tolerance (12,
34). Although death of lymphocytes is an important homeostatic mechanism in the
immune system and maintenance of peripheral tolerance to self antigens, AICD of
16

lymphocytes is disadvantageous in adoptive immunotherapy. Moreover, IL-2 is essential
for regulatory T cells (Tregs) differentiation which may also hinder the effectiveness of
adoptive immunotherapy. Naturally occurring Tregs (CD4+ CD25+ T cell population with
constitutively expressed transcription factor forkhead box P3 or Foxp3) are important in
controlling immunological tolerance to self-antigens but tumor-associated antigens can
also be expressed as self which can enhance tumor protection (35).
Thus, other cytokines from the common cytokine receptor γ-chain family, namely
IL-7 and IL-15, were explored as the alternative cytokine supplements. Both IL-7 and IL15 are essential regulators of T cell survival (33). Also, clear roles for IL-7 and IL-15 have
been described in the maintenance of memory CD8 T cells. The memory CD8 T cell pool
consists of effector memory cells that reside in peripheral tissues and central memory T
cells located in lymphoid organs. Effector memory CD8 cells resemble phenotypic and
functional similarities to effector cytotoxic CD8 T cells but persist even after antigen
clearance. Central memory CD8 T cells are distinct from naïve, effector, and effector
memory CD8 T cells. Characteristic phenotype properties of central memory cells include
the expressions of CD44high, CD62Lhigh, IL-2Rβ+, Ly-6Chigh, and CCR7+. These markers
are downregulated on effector memory T cells (36).
Physiologically, IL-7 is produced by a variety of stromal cells, keratinocytes,
dendritic cells, neurons, and endothelial cells. IL-7 is critical for lymphopoiesis, T cell
homeostasis, maintenance, and it also promotes T cell cytolytic responses. IL-7 is also an
attractive cytokine agent for restoration of T cell activities in tumor-bearing hosts due to
high level of the IL-7 receptor (CD127) expression on naïve T cells (37). While IL-7
17

receptors are found on naïve T cells, they are first downregulated after activation but then
re-expressed on a subset of activated CD8 T cells that progress to become memory T cells
(33). Memory T cells have an increased ability to survive in vivo when compared with
naïve T cells. As IL-7 is a survival factor and memory CD8 T cells express high levels of
IL-7Rα, so IL-7 may transmit the same survival signals to memory CD8 T cells as it does
to naïve CD8 T cells (22).
Although IL-15 was originally identified as a cytokine with IL-2-like activity due
to its common β- and γ-chain receptors, there are numerous data that support the idea that,
unlike IL-2, IL-15 signals are important in maintenance of memory CD8 T cells (38). In
fact IL-15 is a more potent proliferative agent for memory CD8 T cells than IL-2.
Furthermore, IL-15 and IL-15Rα are required to maintain normal numbers of antigenspecific memory CD8 T cells. Tan et al., using a cytokine knockout animal model, showed
that in the absence of both IL-7 and IL-15, homeostatic proliferation of memory CD8 T
cells completely failed.
Our lab has previously shown that bryostatin-1 and ionomycin (B/I) selectively
activate tumor-reactive T cells with low expression of the lymph node homing receptor, Lselectin (CD62Llow ), considered a marker for active effector cells. These CD62Llow
lymphocytes demonstrated higher anti-tumor activity both in vitro and in vivo. However,
these lymphocytes were cultured only in IL-2 (28). In a more recent report, we combined
the effects of IL-7 and IL-15 on tumor DLN lymphocytes also activated in B/I. Compared
to the cells grown in IL-2 alone, these IL-7/15 cells demonstrated greater proliferation and
survival in the B16 melanoma model. Also IL-7/15 cells yielded higher in vitro interferon18

gamma release and higher number of CD8 T cells with a central memory phenotype.
However, in vivo adoptively transferred IL-7/15 cells were only slightly more effective
against B16 lung metastases when compared to IL-2 cultured cells (39). However, in our
unpublished report, we have used the 4T1 mammary carcinoma model to show
significantly greater anti-tumor responses of IL-7/15 grown cells when used for AIT even
at lower doses (20 and 40 million cells) (see appendix B). 4T1 is a poorly immunogenic,
highly aggressive, metastasizing cancer. Unlike treating i.v. infusion-induced pulmonary
metastases of B16 melanoma model, the 4T1 model aims to treat subcutaneous solid
tumors and spontaneous metastases. Based on these findings, using the less immunogenic
4T1 mammary carcinoma model, we aimed to investigate the proliferation and phenotypes
of the tumor DLN lymphocytes activated in B/I and expanded in IL-7/15 compared to
culture in IL-2.

2.2 Materials and Methods
Mice
Virus-free BALB/c mice (National Cancer Institute) were used between 8 and 12
weeks of age. Animals were caged in groups of 6 or fewer and provided food and water ad
libitum. All guidelines at Virginia Commonwealth University, which conform to the
American Association for Accreditation of Laboratory Animal Care and the U.S.
Department of Agriculture recommendations for the care and humane experimental use of
animals, were followed.
Tumor Cell Line
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4T1 mammary tumor cells were kindly provided by Dr. Jane Tsai at the Michigan
Cancer Foundation, Detroit, Michigan. Cells were maintained in complete Dulbecco's
Modified Essential Medium (DMEM) with 10% heat-inactivated fetal calf serum
(Hyclone, Logan,UT), 1 mM sodium pyruvate (Mediatech, Inc, Herndon, VA), 100 U/ml
penicillin (Invitrogen, Grand Island, NY), 100 mg/ml streptomycin, 0.075% sodium
bicarbonate, and 10mM HEPES buffer. All cells were incubated in 250 ml T-flasks (PGC,
Gaithersburg, MD) at 37 °C in humidified air with 5% CO2. Tumor cells were harvested
for inoculation of mice with 0.05% trypsin–EDTA (Invitrogen), washed twice with 1×
PBS and resuspended in 1× PBS.
Draining Lymph Node (DLN) Sensitization and Harvesting DLN Cells
BALB/c mice were inoculated in one hind footpad with 1 x 106 viable 4T1
mammary tumor cells. Ten days after sensitization, mice were euthanized by CO2
inhalation and ipsilateral popliteal lymph nodes were harvested into complete RPMI under
sterile conditions. Then the lymph node cells were crushed through a metal screen and
single cell suspensions were prepared in complete RPMI.
In Vitro Pharmacologic (Bryostatin and Ionomycin) Activation of Lymphocytes
The single cell suspensions of DLN were washed with RPMI and resuspended in
RPMI at 1 x 106 cells/ml. DLN cells were incubated for 18 h with 5nM bryostatin 1
(kindly provided by the National Cancer Institute, Bethesda, MD), 1mM ionomycin
(Calbiochem, San Diego, CA), and 80U/ml of rIL-2 (Chiron, Emeryville, CA) at 37 °C in
humidified air with 5% CO2.
Expansion of Lymphocytes in Culture
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Bryostatin-1/ionomycin-activated DLN cells were washed three times with
complete warm RPMI and resuspended at 1 x 106 cells/ml. DLN cells were then expanded
in complete RPMI supplemented with an additional 5% heat-inactivated fetal calf serum
with either 40U/ml of rIL-2 or 10ng/ml each of IL-7 and IL-15 (Peprotech Inc, Rocky Hill,
NJ). The cells were allowed to proliferate in culture for an additional 7-9 days and were
split every 2-3 days with fresh cytokines in order to maintain 1x106 cells/ml concentration.
CD8 T Cell Phenotype Assay and Treg Staining by Flow Cytometry
DLN cells were washed with flow buffer (2% fetal bovine serum and phosphate
buffered saline of pH7.4) and brought up to 1 x 106 cells/ml in 100μl. Cells were first
treated with anti-mouse CD16/CD32 (Mouse BD Fc Block) (BD Pharmingen, San Diego,
CA). Cells were stained for 30 minutes for surface markers: anti-mouse PE-conjugated
anti-CD62L-mAb (Biolegend, San Diego, CA); anti-mouse FITC-conjugated anti-CD44mAb and anti-CD25-mAb (Biolegend, San Diego, CA); and anti-mouse PE/CY5conjugated anti-CD8-mAb and anti-CD4-mAb (Biolegend, San Diego, CA). Unstained
cells were used as the negative control. PE-conjugated rat IgG2a,λ was used as the isotype
control for CD62L and Foxp3 (Biolegend, San Diego, CA). FITC-conjugated rat IgM was
used as the isotype control for CD44 and CD25. Secondary intracellular staining for Foxp3
was carried out after fixation and permeabilization using a PE-conjugated anti-mouse
FoxP3 (FJK-16s) staining set (eBioscience, SanDiego, USA). PE/CY5-conjugated rat
IgG2b,κ was used the isotype control for CD8 and CD4 (Biolegend, San Diego, CA). The
freshly stained cells were analyzed on an ELITE Beckman Coulter flow cytometer. 50,000
viable cells per sample were analyzed.
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Cytokine Release Assay
DLN cells that have been activated with B/I cultured in either IL-2 or IL-7/15 were
assayed for IFN-γ secretion in response to specific antigen. The lymphocytes were cultured
in 24-well plates at 2x106 cells/ml with either no stimulants (negative control) or with a
stimulator (irradiated 4T1 mammary tumor cells). Lymphocyte to stimulator ratio was
10:1. After 24 hours of culture, supernatant was harvested and stored at -20°C until
assayed using a mouse IFN-γ ELISA kit (BD Biosciences Pharmingen, San Diego, CA).
Results reported are the mean values of duplicate ELISA wells ± SD.

2.3 Results
DLN cells grown in IL-7/15 expand better in vitro than in IL-2
Wildtype BALB/c mice were inoculated in one hind footpad with viable 4T1
mammary tumor cells to sensitize the lymph nodes. Ten days after inoculation, mice were
euthanized by CO2 inhalation and ipsilateral popliteal lymph nodes were harvested. Then
the lymph node cells were activated with B/I regimen and were grown in vitro either in IL2 or IL-7/15 cytokines for 10 days. As indicated in Figure 1, IL-7/15 cells expand to 12
fold increase by day 3 and IL-2 cells have expanded to 11.5 fold. By day 6, the fold
increase difference between IL-7/15 and IL-2 was striking (40 fold for IL-7/15 and 11.4
fold for IL-2). IL-7/15 cells continued to have higher number of viable cells extending to
day 10 (68 fold for IL-7/15 and 18.9 fold for IL-2).
Phenotypic polarization of cells cultured in IL-7/15 vs. IL2
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We have previously found that B/I regimen preferentially activate CD62Llow cells,
which lead to a T cell population that is functionally enriched for tumor antigen-specific
clones with antitumor activity. Such adoptively transferred cells seemed to reside
predominantly in the CD8 T cell subset. However, these cells had previously only been
expanded in IL-2 in vitro. Thus, we investigated whether the phenotypes of IL-2 expansion
were different from the IL-7/15 expanded cells. On days 2, 6, and 9 of cell expansion,
samples were taken from both IL-2 and IL-7/15 groups and were stained for CD8, CD44
and CD62L. CD8 is a marker used for cytotoxic T cells. CD44 is a cell surface
glycoprotein that is expressed by many cells but among CD8 T cells, its expression is
upregulated after activation and remains high on memory T cells. CD62L, also known as
L-selectin, acts as a homing receptor for T cells to lymph nodes. CD62L marker can also
be used to distinguish subpopulations of the CD8 T memory cell as central memory CD8 T
cells (CD62Lhigh) and effector memory CD8 T cells (CD62Llow). Figure 2 shows
percentages of DLN cell by triple staining for (CD8, CD44, and CD62L) and histogram
(for CD8) on days 2, 6, and 9. On day 2, when both IL-2 and IL-7/15 cells were expanding
on the upward trend of the expansion curve, there is not much difference in the proportion
of CD8+ cells (42.63% for IL-2 and 42.84% for IL-7/15). Percentages representing central
memory (triple positive) for IL-2 and IL-7/15 were also similar (71.51% for IL-2 and
77.11% for IL-7/15). By day 9, when the expansion difference between IL-2 and IL-7/15
cultured cells is the greatest, IL-2 cells have significantly reduced central memory
phenotype (CD44high/CD62Lhigh) but the IL-7/15 group maintained the memory phenotype
(24.44% for IL-2 vs. 52.61% for IL-7/15). Also, IL-7/15 cultured cells maintained a high
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proportion of CD8+ T cells while IL-2 cultured CD8+ cells began to decline (43.9% for
IL-2 and 59.8% for IL-7/15).
Treg staining higher in IL2 group than IL7/15
DLN cells expanded in either IL-2 or IL-7/15 were also analyzed for the presence
of T regulatory cells (Tregs) on the same days. As shown in Figure 3, triple positive
staining for CD4, CD25 and Foxp3 markers indicates Tregs. The histograms for each day
also show viable CD4+ cells for each cytokine groups. On day 2, when the expansion
difference is minimal, both the CD4+ cell population and percentages of Tregs are similar
between IL-2 and IL-7/15 groups. However, as IL-7/15 cultured cells proliferate and
expand more effectively, both the CD4 subset and Tregs decreased for IL-7/15 group
compared to IL-2 group. Treg population declined from 15% to 2.6% of CD4+ cells on day
9. Of note, since the CD4+ population is declining as well (from 41.7% to 35.9%), this
triple stained Treg population is even more reduced in IL-7/15 cultured cells compared to
cells from IL-2. However, IL-2 maintained both the CD4+ subset (42.1%, 43.1% and
52.1% on days 2, 6, and 9 respectively) and the Treg population (14.2%, 7.3%, and 7.6%
on days 2, 6, and 9 respectively).
Tumor specificity by IL-7/15 Group vs.IL-2 Group
DLN cells that have been sensitized by B/I regimen and cultured in either IL-2 or
IL-7/15 were assayed for IFN-γ secretion in response to specific antigen. The lymphocytes
were cultured in 24-well plates at 2x106 cells/ml with either no stimulant (negative control)
or with a stimulator (irradiated 4T1 mammary tumor cells). Lymphocyte to stimulator ratio
was 10:1. Results are shown in Figure 4 and are reported as the mean values of duplicate
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ELISA wells ± SD. Data shown are representative of three independent experiments.
Contrary to our previous findings in B16 melanoma model, IL-2 cultured cells secreted
more IFN-γ than IL-7/15 cultured cells when exposed to irradiated 4T1 mammary tumor
cells. This high in vitro IFN- γ response of IL-2 group to 4T1 cells increased further by day
10 of expansion. Previous studies have shown that this IFN-γ response is tumor antigenspecific (60).

2.4 Discussion
Adoptive cancer immunotherapy relies on the infusion of tumor reactive T cells
into tumor-bearing hosts. This therapy utilizes ex vivo expansion of tumor reactive T cells
where stimulatory pharmacological agents and cytokines can be applied to generate large
numbers of such immune effector cells (40). In the experiments described in this chapter,
we found that tumor DLN cells activated in vitro with B/I and cultured in IL-7/15 alternate
common γ-chain cytokines expanded better than IL-2 cultured cells. This in vitro
expansion finding is consistent with our previous report on the beneficial effects of
combining IL-7 and IL-15 comparative to IL-2 alone in B16 melanoma model. B16
melanoma-sensitized lymph node cells from C57B1/6 mice cultured in IL-7/15
consistently resulted in much greater expansion of viable cells than in IL-2 in more than
ten separate experiments. Not only did IL-7/15 induce greater rapid proliferative activity,
but it also induced prolonged growth of T cells (39).
In addition to generating a large number of ex vivo antigen specific T lymphocytes
to transfer, T cells must also preserve their effector functions and homing abilities of
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trafficking to lymph nodes to induce tumor regression and elimination and protection from
recurrence (41). The major function of CD8 effector T cells is to kill infected cells or
malignant cells expressing viral or tumor antigen. Since cytotoxicity requires direct contact
with the target cell, these cytotoxic cells must be able to migrate to different tissues,
especially to sites of inflammation. This capacity of lymphocytes to enter tissues from
blood depends upon the ability to adhere to endothelial cells while withstanding
hydrodynamic shear stresses exerted by flowing blood. Tethering and rolling mechanisms
are initiated by members of the selectin family (42).
Numerous research findings have indicated that antigen-activated CD8 T cells
differentiate differently in trafficking phenotypes and functions when exposed to various
common receptor γ-chain family cytokines. According to Klebanoff et al., in the presence
of IL-15 cytokine, the CD8 T cells differentiated into central memory cells (a subset of
memory phenotype) while IL-2 stimulated cells assumed a highly differentiated, effector
and effector memory CD8 T cells (43). Our CD8 phenotype staining comparison for both
IL-2 and IL-7/15 showed marked differences between the two groups on day 9 when their
expansion differences are most pronounced. As expected, IL-7 and IL-15 maintained
CD62Lhigh memory CD8 T cell population while IL-2 cultured cells lost much of CD62L
expansion.
Central memory T cells (CD62Lhigh) are located in secondary lymphoid issue with
limited migratory potential and have been proposed to show little cytolytic activity. On the
other hand, effector memory cells (CD62Llow) reside in non-lymphoid tissues with
promiscuous circulatory potential and exhibit cytolytic activity (21). Thus, T cells used for
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current adoptive immunotherapy trials are commonly targeted for effector and effector
memory CD8 T cell phenotypes and functions due to their strong lytic capacity and release
of high IFN-γ (13). However, long-term immunological protection and ability to undergo
self-renewal that can be manifested by memory CD8 T cell population has also attracted
researchers to examine the therapeutic effects of memory T cell transfer therapy (43, 44,
45). Klebanoff et al. evaluated the same IL-2 and IL-15 cultured CD8 T cell populations as
mediators of immune response to an established B16 melanoma. They found that IL-15
cultured antigen-specific cells with central memory T cell phenotype showed greater in
vivo recall response compared to effector memory T cell population. This enhanced
response was associated with the complete eradication of large, established B16 melanoma
tumors (43, 44). We have also found significant anti-tumor responses of IL-7/15 grown
cells when used for AIT in 4T1 mammary carcinoma model. Although AIT with effector
phenotype IL-2 group was successful in inducing tumor regression at a maximum AIT
dose of 75 million cells, it was only memory-centered IL-7/15 group that consistently
showed complete elimination of 4T1 tumor when lower doses (20 and 40 million cells) of
AIT was utilized (unpublished Bear lab data).
Although previously we have observed a correlation between antitumor activity in
vivo and IFN-γ release in vitro, this 4T1 model study showed that tumor regression may
not be completely dependent on this cytokine (28). Klebanoff et al. showed that either IL-2
or IL-15 group produced comparable, dose-dependent amounts of IFN-γ secretion (43, 44).
Contrary to our previous findings in B16 melanoma model (39), IL-2 cultured cells in this
report secreted more IFN-γ in vitro than IL-7/15 cultured cells when exposed to irradiated
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4T1 mammary tumor cells. This finding corresponds to findings of Gattinoni et al. in
which they found that CD8 T cells that acquire effector properties and exhibit increased
antitumor reactivity in vitro (e.g. IFN--γ release) are actually less effective at triggering
tumor regression and cures in vivo. Furthermore, unlike IL-7/15, IL-2 enhances activationinduced cell death (AICD) of lymphocytes as a mechanism of self-tolerance and is
essential for regulatory T cells (Tregs) differentiation which may also hinder the
effectiveness of adoptive immunotherapy (12, 34). We have found that IL-2 cultured cells
maintained higher Treg populations compared to IL-7/15 group.
The result reported here, which demonstrates a different responsiveness of tumor
DLN cells to IL-2 and IL-7/15 for in vitro expansion and memory phenotypes may
contribute to achieving successful AIT. Our findings of IL-7/15 cultured cells effectively
expanding and proliferating ex vivo after B/I treatment correlated with inducing tumor
regression and complete elimination even with smaller doses of T cells needed for AIT
transfer. This phenomenon may be further explored in terms of treating larger established
tumors with fewer transferred cells; perhaps T memory cells grown in IL-7/15 can
demonstrate faster and longer in vivo recall responses than cells grown in IL-2.
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Figure 1: IL-7/15 induces greater growth of tumor DLN cells than IL-2 in vitro
BALB/c mice were inoculated in one hind footpad with 1 x 106 viable 4T1 mammary
tumor cells. Ten days after sensitization, mice were euthanized by CO2 inhalation and
ipsilateral popliteal lymph nodes were harvested. DLN cells were incubated for 18 h with
5nM bryostatin 1, 1mM ionomycin, and 80U/ml of rIL-2 at 37 °C in humidified air with
5% CO2. DLN cells were then expanded in complete RPMI supplemented with an
additional 5% heat-inactivated fetal calf serum with either 40U/ml of rIL-2 or 10ng/ml of
IL-7 and IL-15. IL-7/15 cells expand to 12 fold increase by day 3 while IL-2 cells have
only expanded to 11.5 fold. By day 6, the fold increase difference between IL-7/15 and IL2 is significant (40 fold for IL-7/15 and 11.4 fold for IL-2). IL-7/15 cells continue to have
higher number of cells even to day 10 (68 fold for IL-7/15 and 18.9 fold for IL-2).
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30

Figure 2: IL-7/15 expanded DLN cells maintain central memory CD8 T cell subsets
and show higher CD8 T cells.
4T1 mammary tumor cells sensitized DLN cells were incubated for 18 h with 5nM
bryostatin 1, 1mM ionomycin, and 80U/ml of rIL-2. DLN cells were then expanded in
either 40U/ml of rIL-2 or 10ng/ml of IL-7 and IL-15. On days 2 (2A), 6 (2B), and 9 (2C)
of cell expansion, DLN cell samples were taken for CD8 memory phenotype surface
staining. Percentages of triple positive staining gated on viable CD8 memory population is
indicated by CD8+ CD62L+CD44+ staining in the upper right quadrant. The lower
histogram indicates the percentages for CD8+ T cell population. Fluorescence of 50,000
viable cells per sample was analyzed by flow cytometry. Data shown are representative of
three independent experiments.
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Figure 2B
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Figure 2C

IL-2
12.44%

IL-7/15
24.44%

15.42%

52.61%

4
4
D
C
14.34%

20.57%

CD62L

43.9%

5 9.8%

CD8
Day 9 CD8+ CD62L+ CD44+ memory phenotype staining

34

Figure 3: IL-2 maintains higher number of immunosuppressive T regulatory cells
(Tregs) when compared to IL-7/15 cell group.
DLN cells expanded in either 40U/ml of rIL-2 or 10ng/ml of IL-7 and IL-15 were also
analyzed for Treg (CD4+ CD25+ Foxp3+) population. On days 2 (3A), 6 (3B), and 9 (3C)
of cell expansion, DLN cell samples were stained for Tregs following using a PEconjugated anti-mouse FoxP3 (FJK-16s) staining set. Percentages of triple positive staining
gated on viable CD4 cell population are shown in the upper right quadrant. The lower
histogram indicates the percentages of viable CD4+ T cell population. Fluorescence of
50,000 viable cells per sample was analyzed by flow cytometry. Data shown are
representative of three independent experiments.
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Figure 3B
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Figure 3C
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Figure 4: IL-2 expanded DLN cells show an increase in IFN-γ secretion in response to
specific 4T1 antigen when compared to that of IL-7/15 group over the course of ex
vivo culture.
DLN cells that have been sensitized by bryostatin 1 and ionomycin cultured in either IL-2
or IL-7/15 were assayed for IFN-γ secretion in response to specific and nonspecific
antigen. The lymphocytes were cultured in 24-well plates at 2x106 cells/ml with either no
stimulants (negative control) or with a stimulator (irradiated 4T1 mammary tumor cells).
Lymphocyte to stimulator ratio was 10:1. After 24 hours of culture, supernatant was
harvested and stored at -20°C until assayed using a mouse IFN-γ ELISA kit. Results
reported as the mean values of duplicate ELISA wells ± SD. Data shown are representative
of three independent experiments.
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CHAPTER 3 Gemcitabine-Mediated Suppression of Myeloid-

Derived Suppressor Cells Combined with Adoptive
Immunotherapy to Treat Established Tumor

3.1 Introduction
Adoptive immunotherapy focuses on inducing and expanding cytotoxic T cells and
improving the immune recognition of weak antigens expressed by tumors. However,
tumor-induced immune suppression found in human patients and experimental animals
with malignant tumors significantly impedes the effectiveness of immunotherapy and
cancer immunosurveillance (46). There are several proposed mechanisms that may
modulate tumor-induced immune suppression. Cancer-associated immune suppression can
be facilitated by factors secreted by the tumor, the tumor microenvironment or by
suppressive immune cells such as regulatory T cells. Among these factors, myeloidderived suppressor cells (MDSC) are identified as a major contributor to tumor-associated
immunosuppression (47).
MDSCs are a heterogeneous population of undifferentiated cells that are derived
from the myeloid, macrophage, and dendritic cell lineage. This population includes
granulocyte, macrophage, dendritic cell, and early myeloid progenitors. Increased levels of
MDSCs are reported with numerous pathologic conditions. In animal models, frequency of
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MDSCs can be found in the spleens than in the tumor microenvironment. Human MDSCs
have been reported in the bone marrow and peripheral blood of cancer patients with lung,
breast, and head and neck cancer (46). MDSCs are also known as “immature myeloid
cells,” “inhibitory macrophages,” and “early myeloid cells.” However, immunosuppressive
MDSCs have a key phenotype that can be identified by two major cell surface markers,
CD11b and Ly6G (previously known as Gr-1). CD11b is a specific marker for myeloid
cells of the macrophage lineage and Gr-1 is a marker for granulocytes. MDSCs express
low levels of MHC class II molecules and costimulatory molecules; thus, they do not
induce effective antitumor responses due to the inability to process and present antigens
(48). Furthermore, Yang et al. demonstrated that these CD11b+ Gr-1+ cells can acquire
endothelial cell properties in the tumor microenvironment that can contribute to tumor
angiogenesis in promoting tumor growth. MDSCs also downregulate expressions of the
CD3ζ chains of T cell receptors, inhibiting antigen-specific responses from activated CD4
and CD8 T lymphocytes (49). MDSCs have also been linked to triggering apoptotic death
of CD8 T cells (50).
The immunosuppressive effects of MDSCs can be mediated by multiple
mechanisms. MDSCs stimulate immunosuppressive cytokines, nitric oxide synthase type 2
(iNOS or NOS2) and arginase-I (ARG1) metabolism of L-arginine into reactive oxygen
species (ROS) and nitric oxide (NO). The expansion of MDSCs is associated with
increased levels of growth factors including vescular endothelial growth factor (VEGFs)
which inhibit dendritic cell differentiation. Also, MDSC reduction of CD3ζ chains of T
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cell receptors has been accompanied by an increase in ARG1 activity. Activation of ARG1
limits L-arginine availability in the tumor microenvironment and the formation of urea
which can alter translation of mRNAs, further suppressing T cell functions. Additionally,
high levels of iNOS and NO accompanied by MDSCs suppress IL-2 receptor signaling and
increase reactive oxygen species and reactive nitrogen oxide species. These highly reactive
oxidizing agents damage biological targets and contribute to immunosupression by T cell
apoptosis, increased IL-2 instability, depressed T cell proliferation, and depression of
CD3ζ chain expression (46). By direct contact with macrophages, MDSCs can also
decrease macrophage IL-12 production while increasing IL-10 secretion (47).
Based on these immunosuppressive effects of MDSCs, elimination of MDSCs from
the tumor bearing hosts has been proposed to enhance the adoptive immunotherapy.
Kusmartsev et al. described a strategy of in vivo administration of all-trans-retinoic acid
(ATRA) to tumor bearing animals. ATRA is a naturally occurring isomer of retinoic acid
capable of inducing differentiation of a human leukemia cell line and acute promyelocytic
leukemia cells. In vitro experiments with ATRA significantly reduced the presence of
MDSCs in humans and mice. Combining the administration of ATRA and cancer vaccine
demonstrated reduced immunosuprression and enhanced efficacy of the tumor vaccine in
the animal model (52). Suzuki et al. examined the potential use of a chemotherapeutic
agent, gemcitabine, in combination with immunotherapy to address the
immunosuppressive effects of MDSCs. Gemcitabine HCl (GEM) is 2’-deoxy-2’, 2’difluorocytidine monohydrochloride (β-isomer) is a nucleoside analogue of cytidine that
halts the DNA synthesis phase (S-phase) and blocks the progression of cells through the
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G1/S-phase boundary (53). Their rationale for using GEM treatment were based on the
observations of Nowak et al. that antiproliferative gemcitabine selectively preserves tumorspecific CD4 and CD8 T cells while reducing the number of B cells. This study showed
that administration of GEM at a physiological dose can significantly reduce the number of
MDSCs in the spleens of tumor bearing animals while maintaining CD4 T cells, CD8 T
cells, natural killer cells, and macrophages. Furthermore, the antitumor activity of CD8 T
cells and activated natural killer cells were enhanced (54).
In the weakly immunogenic 4T1 mammary carcinoma model, we have recently
reported that GEM can directly inhibit MDSCs and indirectly reduce the number of
MDSCs by its cytotoxicity to the tumor cells. Based on these findings, AIT was performed
to cure 4-day old 4T1 flank tumors. The donor AIT spleen cells were prepared from tumorbearing mice after in vivo GEM treatment which augmented the in vitro expansion of the
splenic T cells and restored T cell function. However, the AIT treatment with these splenic
T cells was ineffective against the established tumors (55). In this study, we investigate
whether in vivo administration of GEM to the AIT recipient tumor-bearing mice has a
therapeutic effect in eliminating established 4T1 mammary carcinoma. AIT T lymphocytes
from the tumor-draining lymph nodes, rather than spleen cells, were prepared using the
more effective IL-7/15 cytokine expansion protocol mentioned in the previous chapter.

3.2 Materials and Methods
Mice
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Virus-free BALB/c mice (National Cancer Institute) were used between 8 and 12
weeks of age. Animals were caged in groups of 6 or fewer and provided food and water ad
libitum. All guidelines at Virginia Commonwealth University, which conform to the
American Association for Accreditation of Laboratory Animal Care and the U.S.
Department of Agriculture recommendations for the care and humane experimental use of
animals, were followed.
Tumor Cell Line
4T1 mammary tumor cells were kindly provided by Dr. Jane Tsai at the Michigan
Cancer Foundation, Detroit, Michigan. Cells were maintained in complete Dulbecco's
Modified Essential Medium (DMEM) with 10% heat-inactivated fetal calf serum
(Hyclone, Logan,UT), 1 mM sodium pyruvate (Mediatech, Inc, Herndon, VA), 100 U/ml
penicillin (Invitrogen, Grand Island, NY), 100 mg/ml streptomycin, 0.075% sodium
bicarbonate, and 10mM HEPES buffer. B16F10 melanoma tumor cells were kindly
donated by Dr. Rodney Prell at Cell Genesys, Inc., South San Francisco, California.
All cells were incubated in 250 ml T-flasks (PGC, Gaithersburg, MD) at 37 °C in
humidified air with 5% CO2. Tumor cells were harvested for inoculation of mice with
0.05% trypsin–EDTA (Invitrogen), washed twice with 1× PBS and resuspended in 1×
PBS.
Draining Lymph Node (DLN) Sensitization and Harvesting DLN Cells
BALB/c mice were inoculated in one hind footpad with 1 x 106 viable 4T1
mammary tumor cells. Ten days after inoculation, mice were euthanized by CO2 inhalation
and ipsilateral popliteal lymph nodes were harvested into complete RPMI under sterile
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conditions. Then the lymph node cells were crushed through a metal screen and single cell
suspensions were prepared in complete RPMI.
In Vitro Bryostatin and Ionomycin Activation
The single cell suspensions of DLN were washed with RPMI and resuspended in
RPMI at 1 x 106 cells/ml. DLN cells were incubated for 18 h with 5nM bryostatin 1
(kindly provided by the National Cancer Institute, Bethesda, MD), 1mM ionomycin
(Calbiochem, San Diego, CA), and 80U/ml of rIL-2 (Chiron, Emeryville, CA) at 37 °C in
humidified air with 5% CO2.
Expansion of Lymphocytes in Culture
Bryostatin-1/ionomycin-activated DLN cells were washed three times with
complete warm RPMI and resuspended at 1 x 106 cells/ml. DLN cells were then expanded
in complete RPMI supplemented with an additional 5% heat-inactivated fetal calf serum
with 10ng/ml each of IL-7 and IL-15 (Peprotech Inc, Rocky Hill, NJ). The cells were
allowed to proliferate in culture until peak growth and were split every 2-3 days in order to
maintain 1x106 cells/ml concentration.
Treatment of Established Tumors (Adoptive Immunotherapy-AIT)
Recipient BALB/c mice were inoculated subcutaneously into their shaven left
flanks with 1 x 106 4T1 mammary tumor cells in 0.05ml phosphate buffered saline of
pH7.4 (PBS). These tumor bearing mice were then randomly divided into five
experimental groups: 1) untreated control, 2) CYP-only treated control, 3) CYP and GEM
treated, 4) CYP and AIT and 5) CYP, GEM and AIT treated group. Nine days after 4T1
flank injection, cyclophosphamide (CYP) groups received 100mg/kg of CYP
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intraperitoneally (ip) on the left flank. The first administration of in vivo gemcitabine
(GEM) was also given on this day at 60mg/kg intraperitoneally (ip) on the right flank. A
subsequent GEM administration was given on weekly basis from this day on. Twenty-four
hours later after first day administration (day 10), 75 million of IL7/15-expanded DLN
cells for AIT were infused iv in 0.5ml of PBS, 10 days after flank inoculation.
Tumor Measurements
Flank tumor growth was monitored by biweekly measurements of perpendicular
diameters using calipers. When the tumor area (calculated as a product of the two
perpendicular measurements) was greater than 100mm2 or if the mouse appeared sick, the
animal was euthanized by CO2 inhalation.
Sensitization of Spleen Cells and In Vitro Expansion of Splenocytes
BALB/c mice were inoculated subcutaneously into their shaven left flank with
50,000 4T1 mammary cells. On the 20th day, mice were treated with 60mg/kg of GEM
intraperitoneally. Six to 24 h after GEM treatment, spleens were harvested in complete
RPMI, weighed, and crushed through a cell strainer. Splenocytes were resuspended in 1×
ammonium chloride solution to lyse red blood cells and were stained with 0.04% trypan
blue to exclude dead cells. The viable spleen cell numbers were counted under a light
microscope using a Neubauer type hemacytometer. Splenocytes that were expanded were
first subjected to Ficoll density gradient centrifugation to isolate splenic mononuclear cells.
These cells were then washed and brought to a concentration of 1×106 cells/ml and
activated by incubation with bryostatin, ionomycin and IL2 (as above) in 50 ml conical
polystyrene tubes at 37 °C, 5% CO2, for 18 h. Cells were washed three times with warm
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complete RPMI and resuspended at 1×106 cells/ml. Splenocytes were expanded in
complete RPMI supplemented with an additional 5% heat-inactivated fetal calf serum with
IL-7+IL-15 (10 ng/ml each, Peprotech Inc, Rocky Hill, NJ). The cells were allowed to
proliferate in culture until peak growth was reached and were split every 2–3 days to 1×106
cells/ml.
Staining for Myeloid Derived Suppressor Cells (MDSC)
Spleen cells were washed with flow buffer (2% fetal bovine serum and phosphate
buffered saline of pH7.4) and brought up to 1 x 106 cells/ml in 100μl. Cells were first
treated with anti-mouse CD16/CD32 (Mouse BD Fc Block) (BD Pharmingen, San Diego,
CA). Then the cells were stained for 30 minutes with: anti-mouse (FITC-conjugated)
CD11b and anti-mouse (PE-conjugated) Ly-6G/Ly-6C(Gr-1) (Biolegend, San Diego, CA).
Unstained cells were used as a negative control. FITC-conjugated rat IgM was used as the
isotype control or CD11b and PE-conjugated rat IgG2a,λ was used as the isotype control for
Ly-6G/Ly-6C(Gr-1) (Biolegend, San Diego, CA). Staining with anti-CD11b alone or antiGr-1 alone was used as single color positive controls. Stained cells were analyzed (50,000
viable cells per sample) on an ELITE Beckman Coulter flow cytometer.
Separation of MDSC from Splenocytes
BALB/c mice were injected in the flank with 50,000 4T1 carcinoma cells. Twentyone days later, splenocytes were harvested and prepared as described above. Some
splenocytes were set aside as a control group while the remaining cells were sorted to
positively select out the myeloid derived suppressor cells using an Easy Sep PE Selection
Kit (StemCell Technologies, Vancouver, BC, Canada). Splenocytes were treated with FcR
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blocking antibody (BD Biosciences Pharmingen, San Diego, CA) and PE-conjugated antimouse Ly-6G/Ly- 6C (Gr-1) (Biolegend, San Diego, CA). The positive MDSC cells
adhered to the magnetic beads while the MDSC-depleted splenic lymphocytes were
collected separately. Both the MDSC positive and depleted cell groups were counted using
a Neubauer type hemacytometer, and the percentages of MDSC originally present were
calculated. Using the total number of cells for the control groups as the starting point, the
number of cells in the MDSC positive group and MDSC-depleted groups were adjusted by
the calculated MDSC percentage to ensure that the same number of lymphocytes was
plated in each well. In some groups, MDSCs removed with the magnetic beads were added
back to the MDSC-depleted cells at a two-to-one splenic lymphocytesto- MDSC ratio.
Then all groups of splenocytes (control group, MDSCdepleted group and MDSC-addedback group)were activated with B/I plus IL-2 (80 U/ml), and expanded with a combination
of IL-7 and IL-15 (10 ng/ml).
Proliferation Assay
Splenic lymphocytes (unseparated, MDSC-depleted or with MDSC added back, as
described above) were activated with B/I plus IL-2, and cultured in IL-7 and IL-15. On day
4, the activated cells were added to 96-well plates at 5×104 cells/well. After 2 days of
culture, the cells were labeled with 1 μCi/ml of [3H] thymidine (PerkinElmer Life and
Analytical Sciences, Boston, MA) and were harvested 24 h later with a semi-automated
harvester (PHD: Cambridge Technology, Inc., Cambridge, MA). Thymidine uptake was
determined by liquid scintillation counting and expressed as the mean cpm±SD of triplicate
wells.
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Statistical Analysis
Differences between two groups were analyzed with the Student's t-test.
Differences among more than two groups were examined by analysis of variance
(ANOVA) and Tukey–Kramer honestly significant difference test (Tukey's HSD) using
JMPIN software (SAS Institute Inc., Cary, N.C.). Results of tumor growth are presented as
the means±standard errors (SE) of tumor area in each treatment group. In vivo experiments
included three to six mice per group. In vitro assays were repeated at least twice. A p <
0.05 was used throughout to determine significant differences.

3.3 Results
In vitro proliferation of splenic T lymphocytes from 4T1 tumor-bearing mice is suppressed
by MDSCs
BALB/c mice were inoculated subcutaneously in the flank with 50,000 4T1
mammary carcinoma cells. Twenty-one days later, spleens were harvested and MDSCs
were depleted using the magnetic beads. All experimental groups, the unseparated tumor
bearing splenocytes (TB control), MDSC-depleted splenocytes (TB MDSC depleted), and
splenic lymphocytes with MDSC added back in a similar proportion to what was removed
(TB MDSC first depleted then MDSC added back) were pulsed for 18h with bryostatin-1
(5nM), ionomycin (1mM), and IL-2 (80U/ml) then expanded for 8 days in IL-7/15
(10ng/ml). Figure 5A shows the expansion curves for all three groups. The MDSCdepleted group viable cell number expanded 23.4 fold, and both the control groups with
MDSCs showed suppression of growth. Figure 5B shows similar results of proliferation of
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lymphocytes measured by thymidine incorporation. Each cell group was pulsed with 3Hthymidine on day 5 and cells were harvested for beta-scintillation counting the following
day.
In vivo administration of Gemcitabine reduces MDSCs in the tumor bearing host spleen
Using two-color flow cytometry, the number of CD11b+ and Gr-1+ (MDSCs)
population was analyzed in mice bearing large 4T1 flank tumors. As shown in Figure 6,
CD11b+ Gr-1+ cells made up 29.5% of the spleen cells in an animal bearing a large tumor
(100 mm2 in size). Gemcitabine was able to reduce this CD11b+ Gr-1+ cell population
with a single dose of 60mg/kg administered shortly before spleen harvest. Even after a
short period of 6h of GEM treatment, the percentage of CD11b+ Gr-1+ cells in the tumor
spleens begins to decrease to 22.7%. By 12h and 24h, the MDSC population was reduced
to 18.3% and 17.7 % respectively.
Gemcitabine-treated 4T1 tumor bearing host failed to reduce the late stage 4T1 flank tumor
Recipient BALB/c mice were inoculated subcutaneously with 50,000 4T1
mammary tumor cells in the flank. After 9 days, cyclophosphamide (CYP) groups received
100mg/kg of CYP intraperitoneally (ip) on the left flank. The first administration of in vivo
gemcitabine (GEM) was also given on this day at a concentration of 60mg/kg. A
subsequent GEM administration was given on a weekly basis from this day on. On day 10,
IL7/15-expanded DLN cells were infused iv. As shown in Figure 7B, despite our previous
findings of GEM’s cytotoxicity in vitro to 4T1 cells and its inhibiting effects on MDSCs in
vivo, rapid 4T1 tumor kinetics inhibited a complete tumor regression and therapeutic
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effects of this combination chemo-immunotherapy. AIT alone carried out under the same
conditions did not inhibit tumor growth.

3.4 Discussion
Tumor-induced immunosuppression is a major obstacle to successful
immunotherapy and a possible mechanism of tumor escape from immunosurveillance (52,
56). Several studies have identified myeloid-derived suppressor cells (MDSC) with
phenotype of CD11b+ Gr-1+ as an important contributor to tumor immune evasion (50, 54,
56, 57). A significant increase in the level of MDSC in tumor-bearing spleens and bone
marrow is associated with impaired immune reactivity (48). Accumulation of MDSC in
both preclinical models and in human samples has been shown to be associated with
defective dendritic cell function and inhibition of antigen specific T cell responses (57).
Our findings here show that the presence of MDSC suppresses in vitro proliferation of
splenic T cells harvested from tumor-bearing hosts. On the other hand, depletion of MDSC
restored in vitro proliferative capacity.
The mechanisms of MDSC-mediates immunosuppression are diverse. One pathway
involves nitric oxide (NO) as an intercellular multivalent signaling molecule. NO is
synthesized by the oxidation of L-arginine to L-citrulline and NO, a reaction catalyzed by a
family of enzymes called nitric oxide synthases (NOS) and other cofactors including
flavones, tetrahydrobiopterin, and Ca2+. Three types of NOS are known: types 1 and 3 are
constitutively expressed in neuronal tissue and endothelium. An inducible form of NOS
(iNOS or type 2) is expressed in a variety of tissue and cell types, including vascular
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endothelium and macrophages. NO released by MDSC works downstream of the IL-2
receptor, inhibiting the phosphorylation of STAT5, Erk, and Akt, three components of the
IL-2 receptor signaling pathway. NO can also interfere with signaling of many other
cytokines such as IL-1, IL-6, IL-8, IL-10, IL-12, IFN-γ, TNF-α, and TGF-β. Animal
studies with NOS inhibitors and depletion of iNOS have shown NO to be as an important
mediator of MDSC-mediated immunosuppression. In vitro and in vivo studies performed
in iNOS-/- knockout mice indicated that NO was required to inhibit T cell proliferation in
the presence of MDSC. Also, in the presence of superoxide, NO gives rise to peroxynitrite
(ONOO-). Peroxynitrite induces antigen-primed T lymphocyte apoptosis by inhibiting
protein tyrosine phosphorylation via nitration of critical tyrosine residues. However, the
inhibition of T cell proliferation in the presence of either splenic or bone marrow MDSC
from tumor bearing mice was completely reversed when an iNOS inhibitor and a
superoxide dismutase mimetic were added. Suppressive mechanisms that allow MDSC to
inhibit CD8 function require cell-cell contact. This contact is not to induce T lymphocyte
apoptosis but rather to trigger NO secretion by MDSC by IFN-γ (58). Furthermore, tumorinfiltrating MDSC seem to be the primary source of ARG1 activity in tumors, and
treatment with ARG1 inhibitors impairs tumor formation in immunologically intact mice.
Increased ARG1 activity by MDSC has been linked to reduced CD3ζ chains in T cells and
diminished production of IL-2 and IFN-γ. ARG1 activity also leads to depletion of Larginine in the local tumor environment, which induces iNOS to produce superoxide (46).
Other suppressive mechanisms that allow MDSC to inhibit T cell immunity involve
IL-12 and IL-10 production. MDSC can downregulate IL-12 production by macrophages
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and increase their own production of IL-10 in response to signals from macrophages. IL-12
produced by macrophages promotes tumoricidal natural killer cell activity. MDSC may
minimize this NK activity by downregulating IL-12 production. MDSC release of IL-10
interferes with DC maturation and high levels of IL-10 may indirectly block DC function
(47).
Thus, eliminating these myeloid immunosuppressive cells in vivo has been a goal
with the potential of enhancing the antitumor activities of transferred T cells in adoptive
immunotherapy. Surgical removal of the cancer has shown a short-term reduction of
MDSC and restoration of antitumor immunity, though, surgical removal of most metastatic
tumors is not possible. Depletion of MDSC by treating tumor-bearing mice with Gr-1
antibodies has also been linked to reduction of MDSC and reduced tumor growth.
However, because of poor specificity of the Gr-1 monoclonal antibodies, mature
granulocytes were also eliminated, jeopardizing the host’s immune system (58).
Kusmartsev et al. demonstrated both in vitro and in vivo that administration of all-transretinoic acid can dramatically reduce the number of MDSC in tumor-bearing animals and
increased antitumor CD4 and CD8 T cell responses.
More recently, the cytotoxic chemotherapy agent, gemcitabine, has been combined
with AIT to reduce MDSC and enhance antitumor activity. GEM is a commonly used
agent in combination chemotherapy for the treatment of several types of cancers
(mammary, bladder, lung, and pancreatic cancers). Gemcitabine HCl (GEM), 2’-deoxy-2’,
2’-difluorocytidine monohydrochloride (β-isomer), is a nucleoside analogue of cytidine
that halts the DNA synthesis phase (S-phase) and blocks the progression of cells through
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the G1/S-phase boundary, which targets rapidly diving tumor cells (53). GEM has been
reported not only to reduce MDSC but also to lower IL-10 levels, thus, restoring
macrophage production of IL-12 (47). Also, GEM can induce apoptosis of tumor cells,
which can generate more antigen cross presentation. In this report, we showed that even a
short 6 hour GEM in vivo treatment reduces MDSC in the spleens of tumor-bearing mice.
By 24 hour, MDSC were significantly reduced. Accordingly, Suzuki et al. administered a
single dose of GEM (120 mg/kg) in vivo, similar to the equivalent dose used in patients
and observed reduction in MDSC accompanied by increased antitumor activity of CD8 T
cells and activated natural killer cells. Ko et al. also used GEM (60 mg/kg) combined with
immunotherapy to treat Her2/neu induced mammary tumors and showed that this
combined chemotherapy and immunotherapy induced therapeutic antitumor immunity (54,
59).
In our previous report, we found that GEM can reduce the number of CD11b+ Gr1+ population by both its direct inhibitory effect on MDSC and indirectly as a result of its
cytotoxicity to the tumor cells (55). By eliminating the tumors directly, the number of
MDSC maintained by factors secreted from the tumor mass declined. Although GEM
reduced MDSC and restored T cell in vitro functions of splenocytes prepared for AIT,
these splenic T cells still failed to induce tumor regression when transferred to treat 4-day
established 4T1 flank tumors. In this report, we aimed to treat a large 10 day established
4T1 flank tumor (>60mm2) by treating the AIT recipients with gemcitabine. Moreover, we
have prepared the T lymphocytes for AIT from tumor DLN cells which were stimulated in
vitro with B/I and cultured in IL-7/15 for 10 days before AIT. Unlike our previous AIT
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attempts with a limited number of splenic T cells, we have transferred a maximum cell
dose (75 million cells) of T lymphocytes to treat large 4T1 tumors. Despite the successful
AIT preparation, combined therapy of GEM and AIT failed to induce significant tumor
regression of such large established tumors. Also, unlike Suzuki et al. who administered
120 mg/kg of GEM, we used a lower GEM dose (60 mg/kg) to lessen the adverse effects
of the antineoplastics on the activated tumor-specific cytotoxic T cells. Thus, although
GEM treatment can attenuate the MDSC-mediated tumor-suppressive environment, when
treating large tumors in the future, it should be accompanied by other methods such as
surgery or additional cytotoxic agents.
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Figure 5. In vitro proliferation of splenic T lymphocytes from 4T1 tumor-bearing
mice is suppressed by MDSCs.
BALB/c mice were inoculated subcutaneously in the flank with 50,000 4T1 mammary
carcinoma cells. Twenty-one days later, spleens were harvested and MDSCs were depleted
using the magnetic beads. All experimental groups, the unseparated tumor bearing
splenocytes (TB control), MDSC-depleted splenocytes (TB MDSC depleted), and splenic
lymphocytes with MDSC added back in a similar portion to what was removed (TB
MDSC first depleted then MDSC added back) were pulsed for 18h with bryostatin-1
(5nM), ionomycin (1mM), and IL-2 (80U/ml) then expanded for 8 days in IL-7/15
(10ng/ml). Figure 5 (A) shows the expansion curves for all three groups. The MDSCdepleted group expanded to 23.4 fold increase in cell number while both the control groups
with MDSCs showed suppression in growth. Figure 5 (B) shows similar results of
proliferation of lymphocytes measured by thymidine incorporation. Each cell groups were
pulsed with 3H-thymidine on day 5 and cells were harvested for beta-scintillation counting
the following day. Data shown are representative of three independent experiments.
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Figure 5B
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Figure 6: In vivo administration of Gemcitabine reduces MDSCs in the tumor
bearing host spleens
Using two-color flow cytometry, the number of CD11b+ and Gr-1+ (MDSCs) population
was analyzed in mice bearing large 4T1 flank tumors. As shown in Figure 6, CD11b+ Gr1+ cells made up 29.5% of the spleen cells in an animal bearing a large tumor (100 mm2 in
size). Gemcitabine was able to reduce this CD11b+ Gr-1+ cell population with a single
dose of 60mg/kg in vivo administration. Even after a short period of 6h of GEM treatment,
the percentage of CD11b+ Gr-1+ cells in the tumor spleens begins to decrease to 22.7%.
By 12h and 24h, the MDSC population has been reduced to 18.3% and 17.7 %
respectively. Data shown are representative of three independent experiments.
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Figure 7: Adoptive immunotherapy of 75 million IL-7/15 cultured DLN cells in
combination with in vivo administration of GEM were ineffective against 10 day old
subcutaneous 4T1 flank tumors.
Recipient BALB/c mice were inoculated subcutaneously into their shaven left flank
with 1 x 106 4T1 mammary tumor cells in 0.05ml phosphate buffered saline of pH7.4
(PBS). These tumor bearing mice were then randomly divided into five experimental
groups: 1) untreated control, 2) Cyclophosphamide-only treated control (CYP only), 3)
Cyclophosphamide and gemcitabine treated (CYP & GEM), 4) Cyclophopshamide and
AIT (CYP & AIT) and 5) CYP, GEM and AIT treated group (CYP/GEM & AIT). After 9
days of 4T1 flank injection, cyclophosphamide (CYP) groups received 100mg/kg of CYP
intraperitoneally (ip) on the left flank. The first administration of in vivo gemcitabine
(GEM) was also given on this day concentration of 60mg/kg on the right flank. A
subsequent GEM administration was given on weekly basis from this day on. Twenty-four
hours later, 75 million (max dose) of IL7/15-expanded DLN cells for AIT were infused iv
in 0.5ml of PBS, 10 days after flank inoculation. (A) IL-7/15 cultured DLNs expanded to
65 fold by day 10 (AIT day) (B) Data shown is mean tumor area ± SE (6 mice per group).
A significant difference in mean tumor area was found using ANOVA and Tukey-Kramer
honestly significant difference test (Tukey’s HSD) using JMPin software.
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APPENDIX A

The Host Defense Mechanisms.
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APPENDIX B

Recipient BALB/c mice were inoculated subcutaneously 50,000 4T1 mammary
carcinoma. These tumor bearing mice were then randomly divided into five experimental
groups:
1) Untreated control
2) Cyclophosphamide-only treated control (CYP)
3) Cyclophosphamide and AIT with IL-2 expanded 20 million DLN cells (CYP +
AIT (IL-2 20))
4) AIT with IL-2 expanded 40 million DLN cells (CYP + AIT (IL-2 40))
5) AIT with IL-7/15 expanded 20 million DLN cells (CYP + AIT (IL-7/15 20))
6) AIT with IL-7/15 expanded 40 million DLN cells (CYP + AIT (IL-7/15 40))
7) AIT with IL-7/15 expanded 80 million DLN cells (CYP + AIT (IL-7/15 80))
After 3 days of 4T1 flank injection, cyclophosphamide (CYP) groups received 100mg/kg
of CYP intraperitoneally (ip) on the left flank. AIT was performed the following day to
cure 4 day tumor. All IL-7/15 AIT group induced complete tumor regression while IL-2
AIT group had similar kinetics as the CYP only control group. Data shown is mean tumor
area ± SE (6 mice per group). A significant difference in mean tumor area was found using
ANOVA and Tukey-Kramer honestly significant difference test (Tukey’s HSD) using
JMPin software
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